Judge Blocks Charlie Kirk Family’s Request For Transparency In Hearing Evidence

The Kirk family argued that full transparency in this case is necessary to combat conspiracy theorists who continue to point fingers at anyone but the man who confessed to the murder.

Texas's Talarico Scrubbed Website of Statements Supporting 'Trans Kids' and 'Bold, Progressive Ideas' Ahead of Senate Run

Texas Democrat James Talarico's website once promoted his support for "trans kids" and "bold, progressive ideas." That was then. Around the time he launched his Senate campaign in a state that hasn't elected a Democrat to the upper chamber since 1988, that changed, a Washington Free Beacon review found. Today, as Talarico tries to break the Texas Democrats' dry spell, his campaign website makes no mention of his "progressive" values.

The post Texas's Talarico Scrubbed Website of Statements Supporting 'Trans Kids' and 'Bold, Progressive Ideas' Ahead of Senate Run appeared first on .

California Democrat Pushes Bill Increasing Cost For Government Records Requests

'Virtual horror show of governmental non-transparency'

New Docs: Fauci Colluded With Intel Agencies On Covid Cover-Up And Then Lied To Congress About It

'After years of lies, censorship, and cover ups, the American people deserve transparency, truth, and accountability,' said outgoing DNI Tulsi Gabbard.

California Shows Exactly Why Having The Right Election Laws Is So Important

Democrats want voting that is deliberately designed for post-election manipulation by political insiders to achieve desired outcomes.

Bill Gates 'voluntarily' explains his Epstein ties to Congress



Bill Gates knew Jeffrey Epstein was a convicted sex offender. He met with him anyway — for years. On Wednesday, he had to explain that to Congress.

The 70-year-old Microsoft co-founder appeared before the House Oversight and Government Reform Committee for a closed-door, transcribed interview. The session lasted nearly six hours.

'I guess if you're a big deal, you can do more than the rest of us.'

On his way in, Gates told reporters he was "glad to be here voluntarily." He retained Jake Greenberg, who until December was the Oversight Committee's chief investigations counsel. Mid-session, Greenberg reportedly said Gates would not answer questions about his affairs unless directly tied to Epstein.

The paper trail complicates the "voluntary" part.

In February, Rep. Nancy Mace (R-S.C.) formally asked Oversight Chairman James Comer (R-Ky.) to subpoena Gates and compel him to testify under oath.

Comer sent Gates a formal written request in March stating the committee believed he had "information that will assist in its investigation." Before the session on Wednesday, Comer told reporters, "No one's accusing Bill Gates of any wrongdoing."

RELATED: Nancy Mace crashes and burns in South Carolina governor primary

Daniel Heuer/Bloomberg/Getty Images

In his prepared opening statement, Gates expressed regret but denied having extensive knowledge about Epstein's criminal behavior.

"I recall being aware that Epstein had faced prior legal issues, but I did not fully understand the extent of the crimes he committed,” he admitted. “I accepted the introduction without applying the scrutiny I should have."

He also denied ever visiting Epstein's island, ranch, or Florida home.

Epstein pleaded guilty in 2008 to soliciting prostitution from a minor and served jail time as a registered sex offender. Gates claimed he began meeting with Epstein in 2011 over a pitch to unlock billions in global health donations.

By December 2014, Gates said he had cut off contact, concluding Epstein "would never deliver on his promises."

Rep. Melanie Stansbury (D-N.M.) said she directly asked Gates why he continued to associate with a registered sex offender. Gates told her that "getting billions of dollars for global health was worth it,” she said.

After Gates allegedly cut ties in 2014, a departing employee engaged Epstein to negotiate the "separation" — Epstein, Gates claimed, used that channel to learn of his infidelities and pressure him to re-engage.

RELATED: Thomas Massie’s viral Epstein poll reveals stunning top belief: He lives

Kent NISHIMURA/AFP/Getty Images

Rep. Tim Burchett (R-Tenn.) called the questioning "intense" but said Gates was "well coached" and that he didn't expect much new information to surface.

Burchett also broke with GOP leadership over the closed-door format: "I'm big about transparency. ... Let it be wide open." He added, "I guess if you're a big deal, you can do more than the rest of us."

Gates closed his opening statement to Congress with a conditional apology: "If the time I spent with Epstein lent him any credibility, I am deeply sorry."

He left without answering a single question from reporters.

Democrats have repeatedly called for Trump to testify — a push Republicans have so far blocked. But the White House may not be able to stay out of it much longer.

Per Stansbury, Republicans have agreed to call acting Attorney General Todd Blanche — Trump's former lawyer — to testify about White House Epstein strategy sessions.

Comer also announced plans for a transcribed interview with Alan Dershowitz, who negotiated Epstein's 2008 plea deal.

A full transcript is expected in the coming days.

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

Gabbard To Step Down As DNI Following Husband’s ‘Rare’ Bone Cancer Diagnosis

In a major loss for the country, Director of National Intelligence (DNI) Tulsi Gabbard announced Friday her plans to resign from her post at the end of June. The former congresswoman cited her husband’s recent diagnosis of an “extremely rare form of bone cancer” as the reason for her departure. “Abraham has been my rock […]

Marty Makary left behind an FDA families learned not to trust



With so much bad news in the world, it is worth pausing for one encouraging development: Marty Makary finally resigned as commissioner of the Food and Drug Administration last week.

Makary’s tenure at the FDA was marred by internal scandals, forced resignations, dreadful morale, and record staff turnover. More important, he actively sandbagged President Trump’s push to expand clinical trials for rare diseases through the aptly named “right-to-try” framework.

Trump’s next appointee should restore the spirit of right to try and make safe, effective treatments available to children as quickly as possible.

The idea behind right to try is straightforward. Patients with rare conditions, especially those for whom conventional medicine has failed, should have the freedom to pursue experimental treatments that have not yet received full FDA approval. Families fighting the clock have little left to lose. Government should not stand between them and a potentially lifesaving breakthrough.

Makary did.

Members of the MPS community sent more than 10 letters asking Makary for a meeting. They got a form letter in return. Sen. Ron Johnson (R-Wis.) later announced an investigation into the FDA’s denials. Makary’s agency responded by claiming approvals were already “at their peak.” The Wall Street Journal took notice of the FDA’s foot-dragging last year, yet the agency kept rejecting relevant rare-disease treatments in early 2026, including RGX-121 and drugs from Biohaven and Saol Therapeutics.

That stonewalling forced families to escalate.

In March, more than 100 mothers and other advocates staged a mock funeral outside FDA offices. Dressed in black and carrying a real coffin, they sought to draw attention to a group of rare metabolic disorders known as mucopolysaccharidoses. These disorders can show up as mild symptoms such as depression or hyperactivity, or as devastating conditions such as heart disease and skeletal abnormalities.

Many MPS disorders still have no approved treatments, even though they can severely diminish children’s quality of life or kill them outright. The FDA’s regulatory process serves a legitimate purpose. But when a bureaucracy grows so rigid, self-protective, and arrogant that it blocks desperately ill children from access to promising therapies, it stops functioning as a safeguard and starts functioning as a death sentence.

Mark Dant of the Ryan Foundation told Newsweek that some of these drugs were denied because of the FDA’s institutional “dislike” of the accelerated-approval pathway. “For decades we waited for science to find our tomorrows,” he said. “Now it has, and bureaucrats within the agency we pay for are keeping those treatments from our children. We know they are there. … We just cannot reach them.”

RELATED: The FDA seems to care more about celebrities than sick Americans

Valerie Plesch/Bloomberg/Getty Images

Makary’s resignation will not undo the damage. But it does create an opening. We may not yet know what the FDA’s next leadership will look like, but Trump’s appointee should restore the spirit of right to try and make safe, effective treatments available to children as quickly as possible.

Across the world, in the nation of Georgia, parents have staged a protest lasting more than 500 consecutive days, maintaining a round-the-clock presence outside the main government building in Tbilisi. They are willing to risk everything to give their children the best chance at life. Americans should not have to camp outside federal offices for 500 days to get their government to listen.

The new FDA leadership must explain denials of right-to-try clinical trials with enough specificity that sponsors and families understand what evidence could change the decision. Patient and caregiver testimony should shape decisions early, not get folded in at the end as a token gesture. And Congress must demand transparency without turning each drug review into a partisan circus.

Children’s lives are not bargaining chips. The FDA exists to serve the public, not to protect its own bureaucracy from embarrassment. If Makary’s departure opens the door to that truth, families battling ultra-rare diseases may finally have reason to hope.